A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder

International Clinical Psychopharmacology

Volumn 23, Issue 4, 2008, Pages 188-197

  Lieberman, Daniel Z ^a   Montgomery, Stuart A ^b   Tourian, Karen A ^c   Brisard, Claudine ^d   Rosas, Gregory ^c   Padmanabhan, Krishna ^c   Germain, Jean Michel ^d   Pitrosky, Bruno ^d  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c PFIZER INC   (United States)

^d Clinical Research and Development   (France)

Author keywords

Desvenlafaxine; Major depressive disorder; Mixed effect model for repeated measures; Venlafaxine

Indexed keywords

DESVENLAFAXINE; PLACEBO; VENLAFAXINE; ADRENERGIC RECEPTOR AFFECTING AGENT; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; O-DESMETHYLVENLAFAXINE; SEROTONIN UPTAKE INHIBITOR;

ABNORMAL VISION; ADULT; ANALYSIS OF COVARIANCE; ANOREXIA; ARTICLE; ASTHENIA; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; FEMALE; HAMILTON SCALE; HUMAN; IMPOTENCE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; SOMNOLENCE; STATISTICAL ANALYSIS; SWEATING; TACHYCARDIA; TREATMENT RESPONSE; UNITED STATES; VOMITING; XEROSTOMIA; META ANALYSIS;

ADRENERGIC UPTAKE INHIBITORS; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS;

EID: 51349112589     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32830263de     Document Type: Article

References (26)

1. Alfinito PD, Huselton C, Chen X, Deecher DC (2006). Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats. Brain Res 1098:71-78.
2. American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders (DSM-IV). 4th edition. Washington, DC: American Psychiatric Association.
3. Bech P, Gram LF, Dein E, Jacobsen O, Vitger J, Bolwig TG (1975). Quantitative rating of depressive states. Acta Psychiatr Scand 51:161-170.
4. Clement EM, Odontiadis J, Franklin M (1998). Simultaneous measurement of venlafaxine and its major metabolite, oxydesmethylvenlafaxine, in human plasma by high-performance liquid chromatography with coulometric detection and utilisation of solid-phase extraction. J Chromatogr B Biomed Sci Appl 705:303-308.
5. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, et al. (2006). Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 318:657-665.
6. DeLoach LJ, Higgins MS, Caplan AB, Stiff JL (1998). The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 86:102-106.
7. DeMartinis NA, Yeung PP, Entsuah R, Manley AL (2007). A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 68: 677-688.
8. Faravelli C, Cosci F, Ciampelli M, Scarpato MA, Spiti R, Ricca V (2003). A self-controlled, naturalistic study of selective serotonin reuptake inhibitors versus tricyclic antidepressants. Psychother Psychosom 72:95-101.
9. Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Pava JA, Rosenbaum JF (1997). Major depressive subtypes and treatment response. Biol Psychiatry 42:568-576.
10. Gueorguieva R, Krystal JH (2004). Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry 61:310-317.
11. Guy W (1976). Clinical global impressions. Publication ADM 76-338. In: Guy W, editor. ECDEU assessment manual for psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare. pp. 217-222.
12. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
13. Liebowitz M, Yeung PP, Entsuah R (2007). A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry 68:1663-1672.
14. Lipman RS (1982). Differentiating anxiety and depression in anxiety disorders: use of rating scales. Psychopharmacol Bull 18:69-77.
15. Mallinckrodt CH, Kaiser CJ, Watkin JG, Molenberghs G, Carroll RJ (2004). The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA. Clin Trials 1:477-489.
16. Molenberghs G, Thijs H, Jansen I, Beunckens C, Kenward MG, Mallinckrodt C, et al. (2004). Analyzing incomplete longitudinal clinical trial data. Biostatistics 5:445-464.
17. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
18. Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM (1991). Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 23:191-199.
19. Nelson JC, Mazure CM, Jatlow PI, Bowers MB Jr, Price LH (2004). Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 55: 296-300.
20. Raskin A, Schulterbrandt J, Reatig N, McKeon JJ (1969). Replication of factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressives. J Nerv Ment Dis 148:87-98.
21. Segal ZV, Pearson JL, Thase ME (2003). Challenges in preventing relapse in major depression. Report of a National Institute of Mental Health Workshop on state of the science of relapse prevention in major depression. J Affect Disord 77:97-108.
22. Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain J-M, Tourian KA (2007). A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 22:338-347.
23. Steffens DC, Krishnan KR, Helms MJ (1997). Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety 6: 10-18.
24. Thase ME, Entsuah AR, Rudolph RL (2001). Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234-241.
25. Walsh BT, Seidman SN, Sysko R, Gould M (2002). Placebo response in studies of major depression: variable, substantial, and growing. J Am Med Assoc 287:1840-1847.
26. World Health Organization (2001). The World Health Report: 2001-Mental Health: New Understanding, New Hope. Geneva: World Health Organization.